Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us



SABCS 2014 Resources     Registration     Hotel     Presenter Instructions     Support & Exhibits     2014 Overview     Program     Faculty     Travel & Transportation    

Schedule at a Glance
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
 
Product Theatre Schedule
 
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
 
Poster Session OT1
Poster Session OT2
Poster Session OT3
 
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6
 

Program Schedule   >  Schedule at a Glance

 
Spacer
Tuesday, 12/9/14
Spacer
8:00 am - 7:00 pm Registration - Bridge Hall
   
12:00 pm - 1:30 pm

Career Development Forum: A Networking Session for Young Investigators – Room 214

Networking and career development opportunities for early career scientists.   The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the SABCS. Space in the workshop is limited to 220 participants; registrations will be accepted on a first-come, first-served basis and is free of charge.  You can register for this session when you register for the Symposium.

 

12:00-12:05   Introduction

 

12:05-12:35   Panel Discussion

 

  • John R. Benson, Addenbrooke's Hospital, Cambridge, UNITED KINGDOM
  • Suzanne AW Fuqua, Baylor College of Medicine, Houston, TX
  • Douglas Yee, University of Minnesota Masonic Cancer Center, Minneapolis, MN
  • Additional panelists to be announced

 

12:35-1:30    Roundtables (at press time)

 

Balancing Research and Clinical Practice 1

Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA

 

Balancing Research and Clinical Practice 2

John R. Benson, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UNITED KINGDOM and Mehra Golshan, Brigham and Women's Hospital, Boston, MA

 

Balancing Research and Clinical Practice 3

Lisa A. Carey, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

 

Careers in Industry 1

Steven Shak, Genomic Health, Inc., Redwood City, CA

 

Careers in Industry 2

Mika Derynck, Genentech, Inc., South San Francisco, CA

 

Careers in Translational Research

Jorge Reis-Filho, MD, PhD, FRCPath, Memorial Sloan-Kettering Cancer Center, New York, NY

 

Grant Writing - Basic/Translational

Ian Kunkler, Edinburgh Cancer Research UK Centre, The University of Edinburgh, Edinburgh, UNITED KINGDOM

 

Grant Writing - Clinical/Translational

Virginia F. Borges, University of Colorado Denver, Aurora, CO and Matthew J. Ellis, Baylor College of Medicine, Houston, TX

 

How to Become a Clinical Trialist
Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA

 

How to Get the Most Out of your Fellowship Years 1

Ingrid A. Mayer, Vanderbilt-Ingram Cancer Center, Nashville, TN

 

How to Get the Most Out of your Fellowship Years 2

Carey K. Anders, University of North Carolina, Chapel Hill, NC

 

How to Get the Most Out of your Predoctoral Experience

Rong Li, UT Health Science Center at San Antonio, San Antonio, TX

 

Making the Transition from Fellowship to Faculty

Michael T. Lewis, Baylor College of Medicine Cancer Center, Houston, TX

 

Mentoring and Supervising

Suzanne AW Fuqua, Baylor College of Medicine, Houston, TX and Douglas Yee, University of Minnesota Masonic Cancer Center, Minneapolis, MN

 

Negotiating a Job Offer or Promotion - Basic Research

Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA

 

Negotiating a Job Offer or Promotion - Clinical Research

Sharon H. Giordano, University of Texas MD Anderson Cancer Center, Houston, TX

 

Oral Presentation Skills

Gary C. Chamness, Baylor College of Medicine, Houston, TX

 

Publication Strategies

Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

 

Searching for a Job and Interviewing - Basic Research

LuZhe Sun, UT Health Science Center at San Antonio, San Antonio, TX

 

Searching for a Job and Interviewing - Clinical Research

Julia White, The James, OSU Comprehensive Cancer Center, Columbus, OH and Melinda Telli, Stanford University, Stanford, CA

 

The Path Leading to Clinical Trials

David Cameron, Edinburgh Cancer Research Centre, Edinburgh, UNITED KINGDOM

 

Career in Grants Administration

Annabell S. Oh, Susan G. Komen, Dallas, TX

   
12:30 pm - 1:30 pm

Special Forum - Accelerating International Drug Development, Companion Diagnostics, and Their Approval - Hall D

Moderator: Laura J. van 't Veer, PhD

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, CA

Government Perspective

Tatiana M. Prowell, MD
U.S. Food and Drug Administration
Silver Spring, MD

 

Improving access to innovative anticancer medicines: a clinicians viewpoint

Jan H.M. Schellens, MD, PhD

The Netherlands Cancer Institute

Amsterdam, NETHERLANDS

 

Industry perspective on co-development of companion diagnostics with targeted therapies

Eric H. Rubin, MD

Merck & Co.

North Wales, PA

   
2:00 pm - 7:00 pm

Educational Sessions - Ballrooms A & B and Hall D

Supported in part by an educational grant from Susan G. Komen®

Updates on advances in key areas and in technologies available for
translational research. Many of the sessions will provide attendees
with a better understanding of the background leading up to talks they
will hear in the succeeding days, and some of the techniques that will
be used. The presentations should also provide researchers with ideas
and techniques to be considered for their own studies.

   
Spacer
2:00 pm - 3:30 pm

Optimizing Clinical Outcomes and Quality of Life in Breast Reconstruction – Ballroom A

Moderator: John Benson, MD

Cambridge University Hospitals NHS Foundation Trust

Cambridge, UNITED KINGDOM

The impact of patient perspective on outcomes in breast reconstruction

Andrea L. Pusic, MD, MHS

Memorial Sloan-Kettering Cancer Center

New York, NY

Reconstruction for the high risk patient: challenges of chemotherapy, radiation therapy and patient selection

Mehra Golshan, MD

Brigham and Women's Hospital

Boston, MA                                   

Delayed and immediate partial breast reconstruction after breast conserving surgery

Krishna B. Clough, MD

L'Institut du Sein - Paris Breast Centre

Paris, FRANCE

HER2 Positive Breast Cancer: Insights from the Lab and Clinic - Ballroom B

Moderator: Mothaffar Rimawi, MD

Baylor College of Medicine

Houston, TX

Mechanisms of HER2 signaling, targeting, and resistance

Mark M. Moasser, MD

University of California

San Francisco, CA

 

Neoadjuvant therapy in HER2 positive breast cancer, latest developments and biomarkers and how it serves as a discovery platform

Sibylle Loibl, MD, PhD

German Breast Group

Neu-Isenburg, GERMANY

Management of metastatic HER2 positive disease: optimizing current therapies and an overview of new agents in development

Ian Krop, MD, PhD

Dana-Farber Cancer Institute

Boston, MA

 

Neoadjuvant Treatment of ER+ Breast Cancer Hall D

Moderator: Mitchell Dowsett, PhD, FMedSci

Royal Marsden Hospital

London, UNITED KINGDOM

Clinical insights on the neoadjuvant therapy of ER+ breast cancer

David A. Cameron, MD

Edinburgh Cancer Research Centre

Edinburgh, UNITED KINGDOM

Biomarkers for clinical management and research

Mitchell Dowsett, PhD, FMedSci

Royal Marsden Hospital

London, UNITED KINGDOM

 

Integration of novel targeted agents with endocrine therapy

Ingrid A. Mayer, MD, MSCI

Vanderbilt University School of Medicine

Nashville, TN
Spacer

 

3:45 pm - 5:15 pm

 

New Insights in Breast Radiation – Ballroom A

Moderator: Richard L. Crownover, MD, PhD

UT Health Science Center

San Antonio, TX

Which patients can safely avoid radiation after breast conserving surgery?

Ian H. Kunkler, MB BCHIR, DMRT, FRCR

NHS Lothian Universities Hospitals Trust

Edinburgh, UNITED KINGDOM

 

What have we learned from the randomized trials of partial breast RT?

Ivo A. Olivotto, MD, FRCPC

University of Calgary and Tom Baker Cancer Centre

Calgary, CANADA

 

What is the value of internal mammary chain RT and how can we deliver it safely?

John R. Yarnold, BSC, MB BS, MRCP, FRCR, FRACR

Royal Marsden and Institute of Cancer Research

London, UNITED KINGDOM

Breast Cancer Survivorship: One Size Does Not Fit All – Ballroom B

Moderator: Polly Niravath, MD

Baylor College of Medicine

Houston, TX

Adherence and persistence with adjuvant aromatase inhibitor therapy

Norah Lynn Henry, MD, PhD

University of Michigan

Ann Arbor, MI

 

Second primary cancers among breast cancer survivors: Incidence and risk factors

Christopher I. Li, MD, PhD

Fred Hutchinson Cancer Research Center

Seattle, WA

 

Patient centered treatment summaries and survivorship care plans: enhancing clinical, cultural and linguistic responsiveness

Kimlin Tam Ashing, PhD

City of Hope Medical Center

Duarte, CA

 

Introduction to Immunotherapy Hall D

Moderator: Douglas Yee, MD

University of Minnesota

Minneapolis, MN

 

Immunotherapeutic approaches to breast cancer

Mary L. (Nora) Disis, MD

University of Washington

Seattle, WA

 

Immune checkpoints and cancer therapy

Jeffrey S. Weber, MD, PhD

Moffitt Cancer Center

Tampa, FL

 

Tumor infiltrating lymphocytes in breast cancer

Sherene Loi, MBBS (Hons), FRACP, PhD

Peter MacCallum Cancer Centre

Melbourne, AUSTRALIA
Spacer

 

5:30 pm - 7:00 pm

 

Breast Cancer is a Global Disease – Biology, Environment and Health Care Delivery - Ballroom A

Moderator: Melissa Bondy, PhD

Baylor College of Medicine

Houston, TX

 

Global patterns of breast cancer

Benjamin O. Anderson, MD

University of Washington

Seattle, WA

 

Biology vs. Environment – Is biology driving health care disparities

Patricia Thompson, PhD

Stony Brook University

Stony Brook, NY

 

Breast cancer in developing countries - challenges and opportunities

Hamdy A. Azim, MSc, MD

Cairo University

Cairo, EGYPT

 

Molecular Heterogeneity – Ballroom B

Moderator: Andrea L. Richardson, MD, PhD

Dana-Farber Cancer Institute

Boston, MA

 

Spatial and temporal evolution of breast cancer

Lucy Yates, MBBS, MRCP

The Wellcome Trust Sanger Institute

London, UNITED KINGDOM

 

Circulating plasma tumor DNA as biomarkers for breast cancer therapy

Ben Ho Park, MD, PhD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, MD

Epigenetic heterogeneity in cancer

Kornelia Polyak, MD, PhD

Dana-Farber Cancer Institute

Boston, MA

 

Triple Negative Breast Cancer - Hall D

Moderator: Nicholas Turner, PhD, FRCP

Royal Marsden and Institute of Cancer Research

London, UNITED KINGDOM

The clinical significance of heterogeneity in triple negative breast cancer

Nicholas Turner, PhD, FRCP

Royal Marsden and Institute of Cancer Research

London, UNITED KINGDOM

 

Targeting the positives in TNBC – platinums, PARPS and novel approaches to high risk disease

Andrew Tutt, PhD

Institute of Cancer Research (ICR)

London, UNITED KINGDOM

 

Adjuvant and neoadjuvant therapy: Current practice and future approaches

Eric P. Winer, MD

Dana-Farber Cancer Institute

Boston, MA
 
Spacer
Wednesday, 12/10/14
Spacer
7:00 am - 5:15 pm

Registration - Bridge Hall

   
7:00 am - 8:00 am Continental Breakfast - Hall C
   
8:00 am - 8:15 am

Opening Remarks - Hall D

   
8:15 am - 8:45 am

Plenary Lecture 1- Hall D

Genome-Directed Therapeutics for Endocrine Therapy Resistant ER+ Breast Cancer

Matthew J. Ellis, MD, PhD

Baylor College of Medicine

Houston, TX

 

8:45 am - 11:15 am

General Session 1 - Hall D

   
11:00 am - 5:00 pm Exhibits - Exhibit Hall C
   
11:15 am - 12:00 pm

William L. McGuire Memorial Lecture Hall D

Pharmacogenomics in the Quest for Precision Endocrine Therapy of Breast Cancer

James N. Ingle, MD

Mayo Clinic

Rochester, MN

 

   
12:00 pm - 1:00 pm

Lunch

   
1:00 pm - 2:00 pm

Clinical Science Forum - Contralateral Prophylactic Mastectomy: Controversies and Trends - Hall D

Moderator: Ismail Jatoi, MD, PhD, FACS

UT Health Science Center
San Antonio, TX

Clinical implications of contralateral prophylactic mastectomy

Ismail Jatoi, MD, PhD, FACS

UT Health Science Center

San Antonio, TX

Contralateral prophylactic mastectomy: Patient preferences and risk perceptions

Ann Partridge, MD, MPH

Dana-Farber Cancer Institute

Boston, MA

 

What are the implications for reconstruction following contralateral prophylactic mastectomy?

Andrea L. Pusic, MD, MHS

Memorial Sloan-Kettering Cancer Center

New York, NY

 

 

   
1:00 pm - 2:00 pm

Basic Science Forum - Discovering Rational Combination Therapies – Ballroom B

Moderator: Carlos Arteaga, MD

Vanderbilt-Ingram Cancer Center

Vanderbilt University

Nashville, TN

Targeting DNA repair in triple negative breast cancer therapy

Alan D'Andrea, MD

Dana-Farber Cancer Institute

Boston, MA

 

Finding effective combination therapies through functional genetics

René Bernards, PhD

Netherlands Cancer Institute

Amsterdam, NETHERLANDS
   
1:00 pm - 2:00 pm

Special Forum - Role of Advocates in Community, Research and Policy – Ballroom A

Moderator: Susan W. Rafte

Pink Ribbons Project

Houston, TX

Community Advocacy

Valarie Worthy, RN, BSN

Duke University

Durham, NC

 

Research Advocacy

Elizabeth S. Frank, BA, Ed.M

Dana-Farber Cancer Institute

Boston, MA

 

Policy Advocacy

Jane Perlmutter, PhD, MBA

Gemini Group

Ann Arbor, MI

 

Funmi Olopade, MD, Panelist

University of Chicago

Chicago, IL

 

Eric P. Winer, MD, Panelist

Dana-Farber Cancer Institute

Boston, MA

   
   
2:15 pm - 3:15 pm

Susan G. Komen® Brinker Awards for Scientific Distinction Lectures - Hall D

 

Joan S. Brugge, PhD

Harvard Medical School

Boston, MA

Building Upon Advances in Cancer Research to Improve Therapeutic Strategies in the Future

 

Mitchell Dowsett, PhD, FMedSci

Royal Marsden Hospital and Institute of Cancer Research

London, UNITED KINGDOM

What relevance have hormones for breast cancer in the genomic era

   
3:15 pm - 5:00 pm

General Session 2 - Hall D

   
5:00 pm - 7:00 pm Poster Discussion 1: Tumor Immunity - Ballroom A
   
5:00 pm - 7:00 pm

Poster Discussion 2: Randomized Clinical Trials: Learning from Successes and Failures - Ballroom B

   
5:00 pm - 7:00 pm

Poster Session 1 & reception - Halls A-B 

   
7:30 pm - 9:30 pm

Open Satellite Event presented by Research to Practice - Marriott Rivercenter, Grand Ballroom (3rd Floor)

What Oncology Clinicians Want to Know - Addressing Current Questions and Controversies in the Management of Breast Cancer

For more information or to register, please visit:

http://www.researchtopractice.com/Meetings/SA2014.

   
Spacer
Thursday, 12/11/14
Spacer
7:00 am - 5:15 pm

Registration - Bridge Hall

   
7:30 am - 9:00 am

Poster Session 2 & continental breakfast - Halls A-B

   
9:00 am - 9:30 am

Plenary Lecture 2 - Hall D

Patient Derived Xenografts - Pre-Clinical Models for Prevention and Treatment of Metastasis

Alana L. Welm, PhD
Oklahoma Medical Research Foundation

Oklahoma City, OK

   
9:30 am - 12:00 pm

General Session 3 - Hall D

   
11:00 am - 5:00 pm Exhibits - Exhibit Hall C
   
12:00 pm - 1:00 pm Lunch
   
1:00 pm - 2:00 pm

Case Discussion 1 - Ballroom A

Moderator: Mothaffar Rimawi, MD

Baylor College of Medicine

Houston, TX

   
1:00 pm - 2:00 pm

Basic Science Forum - Ballroom B

New Insights into Metastatic Progression

Moderator: Xiang Zhang, PhD

Baylor College of Medicine

Houston, TX

Collective invasion in breast cancer is led by specialized cancer cells with basal gene expression

Andrew Ewald, PhD

Johns Hopkins University School of Medicine

Baltimore, MD

Targeting the LIFR-Hippo-YAP pathway as an anti-metastatic strategy

Li Ma, PhD

UT MD Anderson Cancer Center

Houston, TX

   
2:15 pm - 2:45 pm

AACR Outstanding Investigator Award for Breast Cancer Research,
funded by Susan G. Komen® - Exhibit Hall D

Origin of Metastatic Traits in Breast Cancer

Yibin Kang, PhD

Princeton University

Princeton, NJ


   
2:45 pm - 3:45 pm

Mini-Symposium 1 - Hall D

Breast Cancer Predisposition: Germline and Risk

Moderator: Laura J. van 't Veer, PhD

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, CA

 

Characterising cancer risks for carriers of mutations inBRCA1, BRCA2, PALB2 and RAD51C genes

Antonis C. Antoniou, PhD

University of Cambridge

Cambridge, UNITED KINGDOM

 

Risk management of hereditary breast cancer

Banu Arun, MD

UT MD Anderson Cancer Center

Houston, TX

   
3:45 pm - 5:00 pm

General Session 4 - Hall D

   
5:00 pm - 7:00 pm Poster Discussion 3: Intratumoral Heterogeneity - Ballroom A
   
5:00 pm - 7:00 pm Poster Discussion 4: Late Effects of Cancer Therapies - Ballroom B
   
5:00 pm - 7:00 pm

Poster Session 3 & reception - Halls A-B

   
7:30 pm - 9:30 pm

Open Satellite Event presented by Educational Concepts Group, LLC - Marriott Rivercenter

Metastatic Breast Cancer Beyond Progression: Tackling Later-Line Treatment Decisions

 

WEBSITE: http://www.ecgcme.com/mbc

   
7:30 pm - 9:30 pm Open Satellite Event presented by  Letters & Sciences - Marriott Rivercenter, Salon E, Third Floor

PARP Inhibition for BRCA 1/2 Mutation–Associated and Triple Negative Breast Cancer – Advances in Risk Reduction & Treatment

 

http://www.directrsvp.com/parp_inhibition

Spacer
Friday, 12/12/14
Spacer
7:00 am - 5:15 pm

Registration - Bridge Hall

   
7:30 am - 9:00 am

Poster Session 4 & continental breakfast - Halls A-B 

   
9:00 am - 9:30 am

Plenary Lecture 3 - Hall D

Adjuvant Endocrine Therapy in 2015

Nancy E. Davidson, MD

University of Pittsburgh

Pittsburgh, PA

   
9:30 am - 11:30 am

General Session 5 - Hall D

   
11:00 am - 5:00 pm Exhibits - Exhibit Hall C
   
11:30 am- 12:00 pm

AACR Distinguished Lectureship in Breast Cancer Research - Hall D
Genomic Analysis of Inherited Breast and Ovarian Cancer

Mary-Claire King, PhD

University of Washington

Seattle, WA
   
12:00 pm - 1:00 pm

Lunch

   
1:00 pm- 2:00 pm

Case Discussion 2 - Ballroom A

Moderator: Mothaffar Rimawi, MD

Baylor College of Medicine

Houston, TX

   
1:00 pm - 2:00 pm

Basic Science Forum – Ballroom B

How Do Mutations Occur in Breast Cancer?

Moderator: Douglas Yee, MD

University of Minnesota

Minneapolis, MN

APOBEC3B-catalyzed mutagenesis in breast cancer

Reuben Harris, PhD

University of Minnesota

Minneapolis, MN

 

RNA editing and cancer stem cell generation

Catriona Jamieson, MD, PhD

UCSD Moore Cancer Center

La Jolla, CA

   
2:15 pm - 3:15 pm

Mini-Symposium 2 - Hall D

Targeting Epigenetics in Breast Cancer

Moderator: Vered Stearns, MD

Johns Hopkins University School of Medicine

Baltimore, MD

Epigenetic abnormalities in breast cancer

Peter W. Laird, PhD

Van Andel Research Institute

Grand Rapids, MI

 

Targeting epigenetics in breast cancer: clinical implications

Vered Stearns, MD

Johns Hopkins University School of Medicine

Baltimore, MD

   
3:15 pm - 5:00 pm

General Session 6 - Hall D

   
5:00 pm - 7:00 pm Poster Discussion 5: Targeting the PI3K Pathway - Ballroom A
   
5:00 pm - 7:00 pm

Poster Discussion 6: Targeting Hormone Resistance: ER Mutation & Fusion - Ballroom B

   
5:00 pm - 7:00 pm

Poster Session 5 & reception - Halls A-B 

   
7:30 pm

SABCS Special Satellite Symposium presented by Association of Radiotherapy and Oncology of the Mediterranean Area (AROME) - Ballroom B

Minimal requirements and radiation therapy standards for breast cancer in countries with limited resources

 

Website:

http://www.aromecancer.org/arome-special-satellite-symposium-san-antonio-breast-cancer-symposium-sabcs-december-9-13-2014/

 

AROME Program

 

Welcome and Introduction

Adapting means to cancer care in the countries with limited resources

Joseph Gligorov, MD, PHD (President of AROME)

Medical Oncology, Tenon Hospital

Univesity Pierre et Marie Curie. Paris VI

Paris, France

 

New drugs in in the countries with limited resources: how to overcome disparities?

Hamouda Bousse, MD

Univesristy Hospital A. Mami, Ariana

Tunis, Tunisia

 

Adapting evidence based radiotherapy to countries with limited resources

Adela Poitevin, MD

Médica Sur

Mexico City, Mexico

 

Gaps and Disparities:  Bridging the Gap

Fady Geara, MD, PHD

Radiation Oncology

The American University of Beirut Medical Center

Beirut, Lebanon

 

Radiotherapy Techniques According To Means: Minimal requirements and standards

Nuran Bese, MD

Cerrahpasa Medical School

Istanbul University

Istanbul, Turkey

 

Radiotherapy Indications According To Means: Standards and Controversies for maximal efficacy

Yazid Belkacemi, MD, PHD

Henri Mondor Breast Center and Radiation Oncology Department

Univesity of Paris East Creteil (UPEC)

Creteil, France

 

Regional Radiation in Breast Cancer: How to Prevent Toxicities?

Alphonse G. Taghian, MD, PhD

Harvard Medical School

Radiation Oncology and Breast Cancer Research Program

Massachusetts General Hospital

Boston, MA

 

Discussion with panel

Spacer
Saturday, 12/13/14
Spacer
7:00 am - 9:00 am

Registration - Bridge Hall

   
7:30 am - 9:00 am Poster Session 6 & continental breakfast - Hall C
   
9:00 am - 11:00 am

The Year in Review - Hall D

Moderator: C. Kent Osborne, MD

Baylor College of Medicine

Houston, TX

Advances in basic research

Charlotte Kuperwasser, PhD

Tufts University School of Medicine

Boston, MA

Update on Translational Research

Jorge S. Reis-Filho, MD, PHD, FRCPath

Memorial Sloan-Kettering Cancer Center

New York, NY

Adjuvant and neoadjuvant

Harold J. Burstein, MD, PhD

Dana-Farber Cancer Institute

Boston, MA

Update in Metastatic Disease

William J. Gradishar, MD

Northwestern University Feinberg School of Medicine

Chicago, IL

   
11:00 am Adjournment
 
 
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
SABCS 2014 Resources | Registration | Hotel | Presenter Instructions | Support & Exhibits | 2014 Overview | Program | Faculty | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
     line
Copyright 2014 SABCS. All rights reserved. - Privacy Policy